Head Title

The Amsterdam EEGlab: 15+ years of pharma EEG and MEG research in dementia

Register to watch this free webinar on-demand. A link to watch the recording will then be emailed to you shortly after registration. 

This MEGIN Masterclass is presented by guest speaker Willem de Haan discussing "Neurophysiological techniques such as MEG and EEG are valuable in dementia research in various ways. We have been employing them as part of our standard diagnostic procedure in a tertiary memory clinical over the past two decades. With our EEGlab we have provided EEG (and some MEG) analysis and support for multicenter clinical phase 2 trials. In my presentation I would like to talk about our experience in this field, and discuss challenges and lessons learned. In addition, I aim to give an overview of our more fundamental MEG research in dementia, where we focus on advanced analysis of source-space resting-state data with functional connectivity and graph theoretical methods."


"As staff member of the Amsterdam UMC Alzheimer Center, I have over 15 years of experience in neurology, with a focus on cognitive neurology in general, and Alzheimer’s disease (AD) in particular. Since my PhD on functional brain network change in AD, a neurophysiological perspective on dementia has been the focus of my research projects. Research projects range from clinically oriented topics to more fundamental studies. As head of our EEGlab, I coordinate the central analysis of multicenter pharmacological trials with EEG as outcome measure, which also includes providing advice on EEG trial design, and training and supporting participating sites. Utilizing our own Amsterdam dementia cohort EEG and MEG data, we aim to improve diagnostic and prognostic markers for dementia. More fundamental topics include brain network analysis, computational modeling and non-invasive brain stimulation."


*The MEGIN Masterclasses content and speakers selected are only for information purposes and MEGIN does not endorse any applications or treatments mentioned. 

Copyright 2024 © MEGIN – TRIUX™ neo is available for sale in the European Union, UK, Japan, Canada, the United States, as well as certain other countries. In other geographical areas, contact your local MEGIN representative. TRIUX™  neo is intended for use as a magnetoencephalographic (MEG) device that non-invasively detects and displays biomagnetic signals produced by electrically active nerve tissue in the brain. When interpreted by a trained clinician, the data enhances the diagnostic capability by providing useful information about the location relative to the brain anatomy of active nerve tissue responsible for critical brain functions. All other applications are research in nature. Please note that this webinar is being recorded with the permission of our speaker, and will be available on demand.